Given the coordinated expression of EZH2 and TOP2A in HCC, the combined use of EZH2 and TOP2A inhibitors might improve treatment efficacy and overcome the limitations of monotherapy. The gene discussed is TOP2A; the disease is hepatocellular carcinoma.